Home › Kidney Cancer (Renal Cell Carcinoma) › Louisiana › Baton Rouge
Kidney Cancer (Renal Cell Carcinoma) clinical trials in Baton Rouge, LA
3 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in and around Baton Rouge (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- and 2 more
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Louisiana Hematology Oncology Associates LLC, Baton Rouge
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RecruitingPhase 2
- Louisiana Hematology Oncology Associates LLC, Baton Rouge
- Mary Bird Perkins Cancer Center, Baton Rouge
Kidney Cancer (Renal Cell Carcinoma) trials in other cities
- Houston, TX35 studies
- New York City, NY27 studies
- Dallas, TX23 studies
- Nashville, TN23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Pittsburgh, PA15 studies
- Philadelphia, PA15 studies
- Queens, NY15 studies
- Rochester, MN14 studies
Other studies in Baton Rouge
- Obesity15 studies
- Overweight10 studies
- Non-Small Cell Lung Cancer10 studies
- Metastatic Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Lung Cancer8 studies
- Colorectal Cancer8 studies
- Breast Cancer7 studies
- Bladder Cancer6 studies
- Chronic Lymphocytic Leukemia5 studies
- Prostate Cancer5 studies
- COPD5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.